Section 13 · Monograph
Edoxaban
Reviewed Nov 2026FDA label
SavaysaFactor Xa inhibitor (DOAC)
- Forms
- Tab: 15, 30, 60mg
- Dose
- AF stroke prevention: 60mg once daily (30mg if CrCl 15-50)
- MOA
- Direct factor Xa inhibition
Black Box Warning
- Reduced efficacy in nonvalvular AF patients with CrCl above 95mL/min — use another anticoagulant
- Premature discontinuation increases the risk of ischemic events
- Spinal/epidural hematoma risk with neuraxial anesthesia or puncture
Indications
- Reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillationFDA-labeled
- Treatment of DVT/PE after 5-10 days of parenteral anticoagulationFDA-labeled
Mechanism of Action
- Direct factor Xa inhibitor
Full Dosing
Renal
- AF: 60mg once daily if CrCl 51-95mL/min; 30mg once daily if CrCl 15-50mL/min
- Do not use for AF if CrCl above 95mL/min
- VTE: 60mg once daily; 30mg if weight 60kg or less, CrCl 15-50mL/min, or certain P-gp inhibitors
Contraindications
- Active pathological bleeding
- Severe hypersensitivity to edoxaban
Drug Interactions
- P-gp inducers (rifampin) reduce levels — avoid
- Anticoagulants, antiplatelets, NSAIDs increase bleeding risk
Adverse Effects
- Bleeding
- Anemia
- Rash and abnormal liver tests
Monitoring Parameters
- CrCl before starting and periodically
- CBC
- Bleeding signs
Pregnancy & Lactation
- Limited data; avoid in pregnancy
- Avoid during breastfeeding